Further downstream, mitogen-activated protein kinases (MAPK), MYC, and nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) signaling is involved, pathways that can also be targeted for cancer therapy [12,13]. The gene discussed is NFKB1; the disease is cancer.